TrialSignal transduction and targeted therapy2024

SHR-A1811 (antibody-drug conjugate) in advanced HER2-mutant non-small cell lung cancer: a multicenter, open-label, phase 1/2 study.

Ziming Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.